{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T21:59:53Z","timestamp":1780696793630,"version":"3.54.1"},"reference-count":0,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHEOR"],"abstract":"<jats:p>Background: Nonadherence to medication is prevalent in persons diagnosed with schizophrenia, thus increasing the likelihood of relapse, poor health outcomes, hospitalization, high treatment costs, and high rates of both violent and non-violent offenses.\n\nObjective: To assess the association between long-acting injectable (LAI) antipsychotic use and criminal justice system encounters in patients with schizophrenia or schizoaffective disorder.\n\nMethods: This retrospective follow-up study was conducted among patients aged \u226518 years treated for schizophrenia or schizoaffective disorder at a community mental health center in Akron, Ohio, between January 1, 2010, and June 15, 2016. The incidence of criminal justice system encounters at 6 months, 1 year, and 2 years pre- versus post-LAI antipsychotic initiation was assessed. A subanalysis was conducted for individuals with a history of prior arrest.\n\nResults: Overall, the risk ratio (RR) of having an encounter with the criminal justice system was significantly lower for patients treated with LAI antipsychotics 1 year after initiation of treatment compared with a similar time period prior to initiation (RR [95% confidence interval (CI)]: 0.74 [0.59\u20130.93]; P&lt;0.01) and 2 years (0.74 [0.62\u20130.88]; P&lt;0.0001). Statistically significant reductions in criminal justice system encounters after treatment than before treatment were observed in the once-monthly paliperidone palmitate (PP1M) cohort. The incidence of arrests was lower in the 6-month (27 vs 85 arrests), 1-year (46 vs 132 arrests) and 2-year (88 vs 196 arrests) periods post-index LAI medication than in the corresponding periods pre-index LAI medication among individuals with a history of prior arrest.\n\nConclusions: Patients with schizophrenia or schizoaffective disorder who were initiated on a LAI antipsychotic medication, specifically PP1M, were less likely to have an encounter with the criminal justice system compared with a similar time period before the initiation of LAI treatment.<\/jats:p>","DOI":"10.36469\/jheor.2021.22979","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T14:23:10Z","timestamp":1621520590000},"page":"63-70","source":"Crossref","is-referenced-by-count":8,"title":["Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters"],"prefix":"10.36469","volume":"8","author":[{"given":"Madhav P.","family":"Bhatta","sequence":"first","affiliation":[{"name":"Kent State University College of Public Health, Kent, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Bista","sequence":"additional","affiliation":[{"name":"Kent State University College of Public Health, Kent, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine C.","family":"El Khoury","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs LLC, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Hutzell","sequence":"additional","affiliation":[{"name":"County of Summit Alcohol, Drug Addiction, and Mental Health Services Board, Akron, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Tandon","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs LLC, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Smith","sequence":"additional","affiliation":[{"name":"County of Summit Alcohol, Drug Addiction, and Mental Health Services Board, Akron, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2021,5,19]]},"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/pmid\/34056030\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:40:44Z","timestamp":1748875244000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/22979-long-acting-injectable-antipsychotic-use-in-patients-with-schizophrenia-and-criminal-justice-system-encounters"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,27]]}},"URL":"https:\/\/doi.org\/10.36469\/jheor.2021.22979","archive":["Portico","Portico","Portico"],"relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"article-number":"22979"}}